Status Awaiting development
Decision None selected
Process TAG
ID number 4004


Key events during the development of the guidance:

Date Update
12 April 2022 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer. Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course.

For further information on our processes and methods, please see our CHTE processes and methods manual